ArticleGynecologic oncology reports2025
Small cell carcinoma of the cervix with syndrome of inappropriate antidiuretic hormone secretion following chemotherapy: A case report and literature review.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Diagnostic challenges in cervical small cell neuroendocrine carcinoma of a reproductive-age woman.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This report aims to present a rare case of severe hyponatremia induced by syndrome of inappropriate antidiuretic hormone secretion (SIADH) following chemotherapy in a patient with small cell carcinoma of the cervix (SCCC). It also reviews the existing literature on this rare phenomenon. Case: A 45-year-old female with SCCC developed acute symptomatic hyponatremia (sodium level 110 mmol/L) three days following cisplatin-based chemotherapy. SIADH was diagnosed, and the patient required intubation and admission to the intensive care unit due to severe agitation and confusion. Despite initial correction of sodium levels, the patient developed recurrent hyponatremia after subsequent chemotherapy cycles that was refractive to first line agents. She required the use of Tolvaptan, a vasopressin type 2 receptor antagonist, for the management of hyponatremia. Conclusions: This case highlights the rare occurrence of severe SIADH in a patient with SCCC, underscoring the complexity of managing electrolyte disturbances in the context of both paraneoplastic syndromes and chemotherapeutic side effect. The severity of our patient's presentation calls attention to the importance of early recognition of SIADH in the differential diagnosis of oncology patients with altered mental status and confusion. Post chemotherapy sodium surveillance could lead to improved patient outcomes, as well as monitoring for signs and symptoms of hyponatremia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.